ArticleProceedings of the National Academy of Sciences of the United States of America2021
A data-driven approach to identify risk profiles and protective drugs in COVID-19.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Renin-Angiotensin Aldosterone System Inhibitors and COVID-19: A Systematic Review and Meta-Analysis Revealing Critical Bias Across a Body of Observational Research.Journal of the American Heart Association · 2022Pooled it
- Thyroid sequelae of COVID-19: a systematic review of reviews.Reviews in endocrine & metabolic disorders · 2021Pooled it
- Systematic Determinants of Global COVID-19 Burden: Longitudinal Time-Series Analysis Using Big Data-Driven Artificial Intelligence.Journal of medical Internet research · 2025Article
- Biomarkers of glucose homeostasis as mediators of the relationship of body mass index and waist circumference with COVID-19 outcomes among postmenopausal women: The Women's Health Initiative.Clinical nutrition (Edinburgh, Scotland) · 2023Article
- Profiling Covid-19 patients with respect to level of severity: an integrated statistical approach.Scientific reports · 2023Article
- Effect of Previous Anticoagulant Treatment on Risk of COVID-19.Drug safety · 2023Article
- Personalized survival probabilities for SARS-CoV-2 positive patients by explainable machine learning.Scientific reports · 2022Article
- The reproducibility of COVID-19 data analysis: paradoxes, pitfalls, and future challenges.PNAS nexus · 2022Article
- Socio-demographic, lifestyle and health characteristics as predictors of self-reported Covid-19 history among older adults: 2006-2020 Health and Retirement Study.American journal of infection control · 2022Article
- Antecedent use of renin-angiotensin system inhibitors is associated with reduced mortality in elderly hypertensive Covid-19 patients.Journal of hypertension · 2022Article
- Angiotensin II Type I Receptor (AT1R): The Gate towards COVID-19-Associated Diseases.Molecules (Basel, Switzerland) · 2022Review
- Predictors of Covid-19 level of concern among older adults from the health and retirement study.Scientific reports · 2022Article
- COVID-19 and the Endocrine System: A Review of the Current Information and Misinformation.Infectious disease reports · 2022Review
- Reply to Gremese et al.: Statistical reasoning to evaluate treatment effects when data are collected with lack of design: Covid-19 experience.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients.PloS one · 2022Article
- A Call for Quality: Substandard Research in Male Sexual and Reproductive Medicine During the COVID-19 Pandemic.The journal of sexual medicine · 2022Article
- CXCL10 levels at hospital admission predict COVID-19 outcome: hierarchical assessment of 53 putative inflammatory biomarkers in an observational study.Molecular medicine (Cambridge, Mass.) · 2021Observational
- Computational identification of repurposed drugs against viruses causing epidemics and pandemics via drug-target network analysis.Computers in biology and medicine · 2021Article
- On zombies, struldbrugs, and other horrors of the scientific literature.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Renin-Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID-19.Journal of the American Heart Association · 2021Article
Corrections and comments
- AssociatedDataset
- Erratum issued
Authors and funding
12 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the COVID-19 pandemic is spreading around the world, increasing evidence highlights the role of cardiometabolic risk factors in determining the susceptibility to the disease. The fragmented data collected during the initial emergency limited the possibility of investigating the effect of highly correlated covariates and of modeling the interplay between risk factors and medication. The present study is based on comprehensive monitoring of 576 COVID-19 patients. Different statistical approaches were applied to gain a comprehensive insight in terms of both the identification of risk factors and the analysis of dependency structure among clinical and demographic characteristics. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus enters host cells by binding to the angiotensin-converting enzyme 2 (ACE2), but whether or not renin-angiotensin-aldosterone system inhibitors (RAASi) would be beneficial to COVID-19 cases remains controversial. The survival tree approach was applied to define a multilayer risk stratification and better profile patient survival with respect to drug regimens, showing a significant protective effect of RAASi with a reduced risk of in-hospital death. Bayesian networks were estimated, to uncover complex interrelationships and confounding effects. The results confirmed the role of RAASi in reducing the risk of death in COVID-19 patients. De novo treatment with RAASi in patients hospitalized with COVID-19 should be prospectively investigated in a randomized controlled trial to ascertain the extent of risk reduction for in-hospital death in COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.